Clinical Trial

Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations

Study acronym: LCP-TAC
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 2, 2024 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized open label study in de novo liver transplant recipients that aims to compare the risk of tacrolimus induced tremors with once daily extended-release formulation, Envarsus, versus the twice daily immediate-release formulation. Both formulations of tacrolimus are currently approved for the prevention of rejection in liver transplant patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-10-20.
Status change: Not Yet Recruiting → Recruiting 2023-12-27
Trial Details
NCT Number NCT05089604
Lead Sponsor University of British Columbia
Collaborators: Paladin Labs Inc.
Conditions Liver Transplantation, Immunosuppression, Neurotoxicity, Tremor, Tacrolimus
Enrollment 124 participants
Start Date 2023-01-09
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-01-02